Predictive significance of pretreatment 18 F-FDG PET volumetric parameters on survival outcomes in pediatric patients with locally advanced undifferentiated nasopharyngeal carcinoma

• Published in: Pediatric blood & cancer 2024-07, Vol.71 (7), p.e30998
• Main Authors: El-Hennawy, Gihan, ElMenawi, Salma, Nasr Said, Eman, Zekri, Wael, Zaghloul, Mohamed, Elsalam, Ahmed Mustafa Abd, El-Fendy, Habiba, Elantably, Ismail
• Format: Article
• Language: English
• Subjects: Adolescent; Child; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Nasopharyngeal Carcinoma - diagnostic imaging; Nasopharyngeal Carcinoma - mortality; Nasopharyngeal Carcinoma - pathology; Nasopharyngeal Carcinoma - therapy; Nasopharyngeal Neoplasms - diagnostic imaging; Nasopharyngeal Neoplasms - mortality; Nasopharyngeal Neoplasms - pathology; Nasopharyngeal Neoplasms - therapy; Positron Emission Tomography Computed Tomography - methods; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Tumor Burden
• ISSN: 1545-5009; 1545-5017
• DOI: 10.1002/pbc.30998

Nasopharyngeal carcinoma (NPC) is a rare pediatric cancer. Most children are first diagnosed with advanced locoregional disease. Identification of patients at higher risk of treatment failure is crucial as they may benefit from more aggressive initial treatment approaches. Fluorine-labeled fluoro-2-deoxyglucose positron emission tomography ( F-FDG PET) has shown promise as a prognostic tool for predicting outcomes. Retrospective study of pediatric patients with locally advanced undifferentiated NPC who underwent F-FDG PET/CT prior to intial treatment. Predictive significance of metabolic PET parameters on survival outcomes were estimated. Thirty-two children were included, age range was 7.1-18 years at the time of diagnosis. The median follow-up duration was 46.1 months. Three patients (9.4%) were classified as AJCC stage IIb, 13 patients (40.6%) as stage IIIa, eight patients (25%) as stage IIIb, and eight patients (25%) as stage IVa. Our findings revealed that high whole-body metabolic tumor volume at the threshold of hepatic reference SUV (WB-MTV-HR) (>135 mL) was associated with significantly lower event-free survival (EFS) compared to the low WB-MTV-HR group (≤135 mL) (3-year EFS: 50% ± 18% vs. 82% ± 8%; p = .015). Additionally, the 3-year overall survival (OS) rates differed significantly between the high whole-body metabolic tumor volume at the threshold of an SUV of 2.5 isocontour (WB-MTV-2.5) group (MTV >74 mL) and the low WB-MTV-2.5 group (MTV ≤74 mL) (63% ± 18% vs. 100%; p = .021). Our study suggests that WB-MTV parameters could serve as significant prognostic factors for disease progression in pediatric patients with locally advanced undifferentiated NPC. However, further prospective studies with larger sample sizes are needed to validate these findings.